The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | 2-year follow-up of MajesTEC-1: teclistamab in R/R multiple myeloma
Surbhi Sidana, MD, Stanford University, Stanford, CA, discusses the two-year follow-up results of MajesTEC-1 trial (NCT04557098) assessing teclistamab treatment in patients with relapsed/refractory (R/R) multiple myeloma. Dr Sidana highlights the extended duration of response and the reduced infection rates observed over time. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
